Shanghai Ruizhou Biotechnology

Shanghai Ruizhou Biotechnology Co., Ltd. is a biopharmaceutical company established in September 2017 by Dr. Xianchao Zhu, a returning expert from the US. The company focuses on the research, development, and industrialization of innovative vaccines and recombinant protein biologies. Dr. Zhu, a University of California biology PhD, has over two decades of experience in new drug and vaccine development at leading global pharmaceutical companies like Pfizer and later served as a department head at the US Pharmacopoeia's R&D center in China. His extensive background includes leading over 25 new drug development projects, with three achieving FDA market approval.

The company's core product is a self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24). This vaccine was created to address the specific pathogenic strains prevalent in China and aims to increase protection coverage from the current 75% to over 90%. It utilizes a novel non-toxic dual-protein carrier technology. Ruizhou Bio has received clinical approval for the vaccine across all age groups. As of June 2025, the clinical research for adults has completed Phase II trials, with Phase III set to begin, while the Phase I trial for infants and young children has yielded initial data.

Ruizhou Biotechnology has secured significant funding, including a strategic investment in 2017 from Changchun High-Tech Group, which, along with its subsidiary BCHT Biotechnology, has invested a total of 316 million RMB for a 50% stake. More recently, the company completed a Series A+ financing round of tens of millions of RMB in June 2025, led by Changxing Fund. To manage its entire value chain, Ruizhou established Shanghai Weizhou Biotechnology in March 2021, a GMP-level pilot R&D and production workshop in Shanghai. Furthermore, it founded Changchun Ruizhou Biopharmaceutical Co., Ltd. in May 2020 to construct a large-scale, international-standard GMP production base in Changchun, with a potential annual capacity of over 100 million vaccine doses.

Keywords: 24-valent pneumococcal conjugate vaccine, PCV24, vaccine development, biopharmaceutical, Dr. Xianchao Zhu, pneumococcal disease, infectious disease prevention, clinical trials, GMP production, recombinant proteins, biologics manufacturing, dual-protein carrier technology, bacterial vaccines, Changchun High-Tech Group, BCHT Biotechnology, biopharma R&D, monoclonal antibodies, China biopharma, clinical-stage company, vaccine industrialization